Relevant publications LMCT

Immune checkpoint blockade combined with IL-6 and TGF-β inhibition improves the therapeutic outcome of mRNA-based immunotherapy.
Bialkowski L, Van der Jeught K, Bevers S, Tjok Joe P, Renmans D, Heirman C, Aerts JL, Thielemans K. Int J Cancer. 2018 Feb 21.

 

Antigen-presenting cell-targeted lentiviral vectors do not support the development of productive T-cell effector responses: implications for in vivo targeted vaccine delivery.
Goyvaerts C, De Vlaeminck Y, Escors D, Lienenklaus S, Keyaerts M, Raes G, Breckpot K. Gene Ther. 2017 Jun;24(6):370-375.

 

Non-invasive assessment of murine PD-L1 levels in syngeneic tumor models by nuclear imaging with nanobody tracers.
Broos K, Keyaerts M, Lecocq Q, Renmans D, Nguyen T, Escors D, Liston A, Raes G, Breckpot K, Devoogdt N. Oncotarget. 2017 Jun 27;8(26):41932-41946.

 

Adjuvant-Enhanced mRNA Vaccines.
Bialkowski L, Van der Jeught K, Renmans D, van Weijnen A, Heirman C, Keyaerts M, Breckpot K, Thielemans K. Methods Mol Biol. 2017;1499:179-191.

 

Particle-mediated Intravenous Delivery of Antigen mRNA Results in Strong Antigen-specific T-cell Responses Despite the Induction of Type I Interferon.
Broos K, Van der Jeught K, Puttemans J, Goyvaerts C, Heirman C, Dewitte H, Verbeke R, Lentacker I, Thielemans K, Breckpot K. Mol Ther Nucleic Acids. 2016 Jun 21;5(6):e326.

 

More publications:

https://www.ncbi.nlm.nih.gov/pubmed/?term=Thielemans+K+AND+Brussel

https://www.ncbi.nlm.nih.gov/pubmed/?term=Breckpot+K